Genome & Company (KOSDAQ: 314130)
South Korea
· Delayed Price · Currency is KRW 2,915.00
-15.00 (-0.51%)
Nov 15, 2024, 9:00 AM KST
Genome & Company Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Operating Revenue | 23,925 | 14,296 | 14,085 | 451.25 | 150.58 | 45.83 |
| Other Revenue | 0 | - | -0 | - | - | - |
| Revenue | 23,925 | 14,296 | 14,085 | 451.25 | 150.58 | 45.83 |
| Revenue Growth (YoY) | 59.64% | 1.50% | 3021.27% | 199.67% | 228.54% | - |
| Cost of Revenue | 11,722 | 10,232 | 8,487 | 77.01 | - | 16.87 |
| Gross Profit | 12,203 | 4,064 | 5,598 | 374.24 | 150.58 | 28.96 |
| Selling, General & Admin | 29,206 | 28,677 | 19,664 | 14,123 | 12,915 | 5,933 |
| Research & Development | 19,969 | 25,666 | 36,793 | 21,263 | 13,669 | 7,773 |
| Other Operating Expenses | - | - | - | - | - | 21.6 |
| Operating Expenses | 53,992 | 59,156 | 63,110 | 36,461 | 26,779 | 13,850 |
| Operating Income | -41,790 | -55,092 | -57,512 | -36,087 | -26,629 | -13,821 |
| Interest Expense | -2,793 | -1,738 | -175 | -54.92 | -1,236 | -2,112 |
| Interest & Investment Income | 4,237 | 4,121 | 850.8 | 458.17 | 112.52 | 113.72 |
| Earnings From Equity Investments | -2,325 | -2,325 | - | - | - | - |
| Currency Exchange Gain (Loss) | -21.72 | -40.56 | -29.46 | -468.02 | 76.85 | -29.22 |
| Other Non Operating Income (Expenses) | 555.17 | 3,252 | -1,112 | 161.16 | -3,418 | -68,819 |
| EBT Excluding Unusual Items | -42,137 | -51,824 | -57,979 | -35,991 | -31,093 | -84,669 |
| Gain (Loss) on Sale of Investments | 62.74 | 46.44 | -54.79 | - | - | - |
| Gain (Loss) on Sale of Assets | -145.21 | -77.11 | 0.69 | -12.93 | -92.58 | - |
| Pretax Income | -42,220 | -51,855 | -58,033 | -36,004 | -31,186 | -84,669 |
| Income Tax Expense | -1,696 | -1,202 | -1,083 | - | - | - |
| Earnings From Continuing Operations | -40,524 | -50,653 | -56,950 | -36,004 | -31,186 | -84,669 |
| Minority Interest in Earnings | 2,639 | 3,187 | 5,112 | 1,887 | 453.56 | - |
| Net Income | -37,885 | -47,466 | -51,838 | -34,117 | -30,732 | -84,669 |
| Net Income to Common | -37,885 | -47,466 | -51,838 | -34,117 | -30,732 | -84,669 |
| Shares Outstanding (Basic) | 29 | 28 | 28 | 27 | 19 | 16 |
| Shares Outstanding (Diluted) | 29 | 28 | 28 | 27 | 19 | 16 |
| Shares Change (YoY) | 3.64% | 0.32% | 4.71% | 39.60% | 20.11% | - |
| EPS (Basic) | -1297.31 | -1680.81 | -1841.50 | -1269.10 | -1595.95 | -5281.23 |
| EPS (Diluted) | -1297.31 | -1681.00 | -1841.50 | -1269.10 | -1596.00 | -5281.23 |
| Free Cash Flow | -36,387 | -51,077 | -50,399 | -29,034 | -19,662 | -10,736 |
| Free Cash Flow Per Share | -1246.01 | -1808.70 | -1790.39 | -1080.03 | -1021.03 | -669.65 |
| Gross Margin | 51.00% | 28.43% | 39.74% | 82.93% | 100.00% | 63.19% |
| Operating Margin | -174.67% | -385.37% | -408.34% | -7997.20% | -17683.84% | -30155.63% |
| Profit Margin | -158.35% | -332.02% | -368.05% | -7560.62% | -20409.23% | -184731.34% |
| Free Cash Flow Margin | -152.09% | -357.28% | -357.83% | -6434.20% | -13057.09% | -23423.41% |
| EBITDA | -33,806 | -46,820 | -48,051 | -33,496 | -25,164 | -13,251 |
| D&A For EBITDA | 7,984 | 8,272 | 9,462 | 2,591 | 1,464 | 570.03 |
| EBIT | -41,790 | -55,092 | -57,512 | -36,087 | -26,629 | -13,821 |
| Advertising Expenses | - | 2,033 | 1,505 | 987.32 | 207.99 | 33.84 |
Source: S&P Capital IQ. Standard template. Financial Sources.